Does Rallies show Form 4 insider transactions for VRDN?

Yes. Rallies tracks VRDN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is VRDN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRDN. It does not provide personalized investment advice.

VRDN (Viridian Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Viridian Therapeutics, Inc. Common Stock (VRDN) is a publicly traded Healthcare sector company. As of May 21, 2026, VRDN trades at $17.55 with a market cap of $1.78B and a P/E ratio of 0.00. VRDN moved +10.36% today. Year to date, VRDN is -41.62%; over the trailing twelve months it is +27.57%. Its 52-week range spans $9.90 to $34.29. Analyst consensus is strong buy with an average price target of $32.08. Rallies surfaces VRDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading VRDN stock inside the company?

Recent VRDN insider activity includes Fairmount Funds Management LLC bought 1.18M, Tousignant Jennifer sold 2.27K, Fairmount Funds Management LLC bought 454.55K, Beetham Thomas W. bought 5.00K, and Mahoney Stephen F. bought 21.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

VRDN Key Metrics

Key financial metrics for VRDN
Metric	Value
Price	$17.55
Market Cap	$1.78B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$34.29
52-Week Low	$9.90
Volume	44
Avg Volume	0
Revenue (TTM)	$70.85M
Net Income	$-342.60M
Gross Margin	0.00%

Recent VRDN Insider Trades

Fairmount Funds Management LLC bought 1.18M (~$20.00M) on May 11, 2026.
Tousignant Jennifer sold 2.27K (~$70.80K) on Dec 31, 2025.
Fairmount Funds Management LLC bought 454.55K (~$10.00M) on Oct 23, 2025.
Beetham Thomas W. bought 5.00K (~$117.05K) on Sep 27, 2024.
Mahoney Stephen F. bought 21.40K (~$499.26K) on Sep 27, 2024.

Latest VRDN News

Viridian Therapeutics Shares Surge 35.6% After REVEAL-2 Phase III TED Success — May 6, 2026
Viridian shares tumble 38% despite Phase III elegrobart achieving up to 63% response — Mar 30, 2026
Viridian’s Phase 3 TED Trial Shows 54% Proptosis and 71% Diplopia Response — Mar 30, 2026

VRDN Analyst Consensus

14 analysts cover VRDN: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.08.

Common questions about VRDN

Who is trading VRDN stock inside the company?: Recent VRDN insider activity includes Fairmount Funds Management LLC bought 1.18M, Tousignant Jennifer sold 2.27K, Fairmount Funds Management LLC bought 454.55K, Beetham Thomas W. bought 5.00K, and Mahoney Stephen F. bought 21.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for VRDN?: Yes. Rallies tracks VRDN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is VRDN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRDN. It does not provide personalized investment advice.